FDA, SEC Disclosure: Standard Procedures Can Help

Law360, New York (June 27, 2007, 12:00 AM EDT) -- In 2004, the Securities and Exchange Commission and the Food and Drug Administration announced steps to enhance cooperation between them to further protect the public from false and misleading statements by public life sciences companies. The agencies developed a centralized process where the FDA could refer potential disclosure matters to the SEC’s Division of Enforcement, and identify FDA point persons and procedures for the SEC to use when gathering information about public life-sciences companies.

Life science companies are frequent defendants in private securities class actions, and...
To view the full article, register now.